Spontaneous hematoma of the thigh associated with antiproteinase-3 antibody in a patient with metastatic squamous cell carcinoma treated with nivolumab

Abstract

We report an unusual case of spontaneous intramuscular hematoma associated with antiproteinase 3 antibody in a patient with metastatic squamous cell carcinoma receiving nivolumab and the medical literature is reviewed.

Keywords

PD-1/PD-L1 inhibitor nivolumab spontaneous hematoma squamous cell carcinoma of lung

Get full access to this article

View all access options for this article.

References

Brahmer

Drake

Wollner

et al.

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167–3175.

Topalian

Hodi

Brahmer

et al.

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443–2454.

Topalian

Sznol

McDermott

et al.

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32: 1020–1030.

Gibney

Kudchadkar

DeConti

et al.

Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res 2015; 21: 712–720.

Robert

Long

Brady

et al.

Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320–330.

Borghaei

Paz-Ares

Horn

et al.

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627–1639.

Brahmer

Reckamp

Baas

et al.

Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123–135.

Gettinger

Horn

Gandhi

et al.

Overall survival and long-term safety of nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015; 33: 2004–2012.

Rizvi

Mazieres

Planchard

et al.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015; 16: 257–265.

10.

Gettinger

Rizvi

Chow

et al.

Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2016; 34: 2980–2987.

11.

Ferris

Blumenschein

Jr Fayette

et al.

Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016; 375: 1856–1867.

12.

Seiwert

Burtness

Mehra

et al.

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016; 17: 956–965.

13.

Ansell

Lesokhin

Borrello

et al.

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311–319.

14.

Sharma

Callahan

Bono

et al.

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016; 17: 1590–1598.

15.

McDermott

Drake

Sznol

et al.

Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol 2015; 33: 2013–2020.

16.

Motzer

Rini

McDermott

et al.

Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 2015; 33: 1430–1437.

17.

Motzer

Escudier

McDermott

et al.

Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373: 1803–1813.

18.

Muro

Chung

Shankaran

et al.

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 2016; 17: 717–726.

19.

Loochtan

Nickolich

Hobson-Webb

. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve 2015; 52: 307–308.

20.

Martin-Liberal

Furness

Joshi

et al.

Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother 2015; 64: 765–767.

21.

Narita

Oiso

Taketomo

et al.

Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab. J Dermatol 2016; 43: 210–214.

22.

Rossi

Sgambato

Chiara

et al.

Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer. Expert Rev Clin Pharmacol 2016; 9: 419–423.

23.

Sreenivas

Nihal

Ettles

. Chronic haematoma or soft-tissue neoplasm? A diagnostic dilemma. Arch Orthop Trauma Surg 2004; 124: 495–497.

24.

Liu

Leslie

Beauchamp

et al.

Chronic expanding hematoma of the thigh simulating neoplasm on gadolinium-enhanced MRI. Skeletal Radiol 2006; 35: 254–257.

25.

Cebesoy

Tutar

Arpacioglu

. Spontaneous giant expanding thigh hematoma mimicking soft tissue neoplasm. Joint Bone Spine 2008; 75: 64–66.

26.

Negoro

Uchida

Yayama

et al.

Chronic expanding hematoma of the thigh. Joint Bone Spine 2012; 79: 192–194.

27.

Everhart

Fajolu

Mayerson

. Spontaneous, chronic expanding posterior thigh hematoma mimicking soft-tissue sarcoma in a morbidly obese pregnant woman. Am J Orthop (Belle Mead NJ) 2015; 44: E29–E31.

28.

Jennings

Chang

Savige

. Anti-proteinase 3 antibodies, their characterization and disease associations. Clin Exp Immunol 1994; 95: 251–256.

29.

Wilde

Snable

Griffith

et al.

Characterization of two azurphil granule proteases with active-site homology to neutrophil elastase. J Biol Chem 1990; 265: 2038–2041.

30.

Manusow

Khoja

Pesin

et al.

Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma. J Immunother Cancer 2014; 2: 41–41.